Accordingly, ET-1 stimulation increases BCL2 expression in CLL and treatment with macitentan prevents this unwanted effect that limits ABT-199 efficacy towards CLL cells (Figure 3F). This evidence concerns the gene EDN1 and B-cell chronic lymphocytic leukemia.